<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320311419175</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320311419175</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association of angiotensin II type 1-receptor gene polymorphisms with the risk of developing hypertension in Mexican individuals</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Martínez-Rodríguez</surname><given-names>Nancy</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311419175">1</xref>
<xref ref-type="aff" rid="aff2-1470320311419175">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Posadas-Romero</surname><given-names>Carlos</given-names></name>
<xref ref-type="aff" rid="aff3-1470320311419175">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cardoso</surname><given-names>Guillermo</given-names></name>
<xref ref-type="aff" rid="aff3-1470320311419175">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pérez-Rodríguez</surname><given-names>José Manuel</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311419175">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pérez-Hernández</surname><given-names>Nonanzit</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311419175">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vallejo</surname><given-names>Maite</given-names></name>
<xref ref-type="aff" rid="aff4-1470320311419175">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Vargas-Alarcón</surname><given-names>Gilberto</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311419175">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320311419175"><label>1</label>Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico</aff>
<aff id="aff2-1470320311419175"><label>2</label>Graduate Studies in Biomedical Sciences, Universidad Nacional Autónoma de México, Mexico City, Mexico</aff>
<aff id="aff3-1470320311419175"><label>3</label>Department of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico</aff>
<aff id="aff4-1470320311419175"><label>4</label>Sociomedical Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico</aff>
<author-notes>
<corresp id="corresp1-1470320311419175">Gilberto Vargas-Alarcón, Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez. Juan Badiano 1, Sección XVI, Tlalpan, Mexico City, Mexico. Email: <email>gvargas63@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>133</fpage>
<lpage>140</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><italic>Introduction</italic>: Hypertension is a complex disease in which a significant interaction between genetic and environmental factors takes place. The renin–angiotensin system plays an important role regulating blood pressure to maintain homeostasis and vascular tone. In the present work, the role of angiotensin II type 1-receptor (AGTR1) gene polymorphisms as susceptibility markers for hypertension was evaluated.</p>
<p><italic>Materials and methods</italic>: Five polymorphisms in the <italic>AGTR1</italic> gene were genotyped by 5′ exonuclease TaqMan genotyping assays in 239 hypertensive and 371 non-hypertensive individuals.</p>
<p><italic>Results</italic>: A similar distribution of rs275651, rs275652, rs275653, and rs5183 polymorphisms was observed in both studied groups. Different distribution of rs5182 genotypes was observed between the studied groups (<italic>p</italic> = 0.016). According to the co-dominant model, individuals with rs5182 <italic>CC</italic> genotype have a 1.83-fold increased risk of developing hypertension (<italic>p</italic> = 0.009). Polymorphisms were distributed in two blocks: block 1 included the rs275651, rs275652, and rs275653 polymorphisms, whereas block 2 included the rs5183 and rs5182 polymorphisms. Individuals with hypertension showed increased frequency of ‘<italic>CA</italic>’ haplotype of block 2 when compared to non-hypertensive individuals (<italic>p</italic> = 0.015, odds ratio = 1.33).</p>
<p><italic>Conclusion</italic>: The results suggest that the rs5182 gene polymorphism could be involved in the risk of developing hypertension in Mexican individuals.</p>
</abstract>
<kwd-group>
<kwd>Angiotensin II type 1 receptor</kwd>
<kwd>genetic susceptibility</kwd>
<kwd>hypertension</kwd>
<kwd>polymorphisms</kwd>
<kwd>renin–angiotensin system</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320311419175" sec-type="intro">
<title>Introduction</title>
<p>Hypertension plays a major etiologic role in the development of cerebrovascular disease, ischemic heart disease, cardiac, and renal failure. Treating hypertension has been associated with about a 40% reduction in the risk of stroke and about a 15% reduction in the risk of myocardial infarction.<sup><xref ref-type="bibr" rid="bibr1-1470320311419175">1</xref></sup> Although treatment of hypertension has been shown to prevent cardiovascular disease and to extend and enhance life, hypertension remains inadequately managed. In addition, hypertension often coexists with other cardiovascular risk factors, such as smoking, diabetes, hyperlipidemia, and obesity. Hypertension is a complex disease with important participation of environmental, demographic, and genetic factors;<sup><xref ref-type="bibr" rid="bibr2-1470320311419175">2</xref>,<xref ref-type="bibr" rid="bibr3-1470320311419175">3</xref></sup> approximately 30% of the interindividual variability in blood pressure is genetically determined.<sup><xref ref-type="bibr" rid="bibr4-1470320311419175">4</xref></sup></p>
<p>Special attention has been given to the study of genes implicated in the renin–angiotensin system. Molecules of this system contribute importantly to the regulation of vascular tone, blood pressure, cardiovascular remodeling, and electrolyte and volume homeostasis.<sup><xref ref-type="bibr" rid="bibr5-1470320311419175">5</xref></sup> The major biologically active product of this system is angiotensin II, which is a peptide with multiple functions, including vasoconstriction, aldosterone production, and noradrenaline release from sympathetic nerve endings. It has hypertropic and hyperplastic effects on vascular smooth muscle and cardiomyocytes, synthesis of the extracellular collagen matrix, and is tightly intertwined with the cascade of inflammatory, thrombotic, and fibrotic factors.<sup><xref ref-type="bibr" rid="bibr6-1470320311419175">6</xref></sup> These effects are mediated directly and indirectly via two distinct receptors, namely angiotensin II receptor type 1 (AGTR1) and type 2 (AGTR2).<sup><xref ref-type="bibr" rid="bibr7-1470320311419175">7</xref></sup> The AGTR1 receptor is present predominantly in vascular smooth muscle cells, and AGTR2 receptor is present in the uterus, brain, and adrenal medulla. Both subtypes are also expressed in the adrenal cortex and kidney.<sup><xref ref-type="bibr" rid="bibr8-1470320311419175">8</xref></sup> Because of the physiological role of the AGTR1 in the cardiovascular system, the gene that encodes this molecule is an excellent candidate in the etiology of hypertension and other cardiovascular diseases.</p>
<p>The <italic>AGTR1</italic> gene is located on chromosome 3q21-25 and has a length of more than 55 kb.<sup><xref ref-type="bibr" rid="bibr9-1470320311419175">9</xref></sup> This gene presents several polymorphisms with important participation in the susceptibility to diseases.<sup><xref ref-type="bibr" rid="bibr10-1470320311419175">10</xref>–<xref ref-type="bibr" rid="bibr13-1470320311419175">13</xref></sup> The present study was based on the assumption that the <italic>AGTR1</italic> gene polymorphisms have a measurable influence on the hypertension mechanism and contribute to, or reduce, this disease. Thus, the aim of the present study was to establish the role of the <italic>AGTR1</italic> gene polymorphism in the risk of developing hypertension in Mexican Mestizo individuals.</p>
</sec>
<sec id="section2-1470320311419175" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1470320311419175">
<title>Individuals studied</title>
<p>This study included a group of 239 hypertensive individuals (120 men and 119 women) referred to our institution. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg, a diastolic blood pressure ≥ 90 mmHg, or the use of at least one class of antihypertensive agents. A group of 371 non-hypertensive individuals (168 men and 203 women) were recruited from the blood bank of our Institute; these individuals had a systolic and diastolic of less than 140/90 mmHg and had neither a personal history of elevated blood pressure nor a familial history of hypertension. All subjects included in the study were ethnically matched, and we considered as Mexican Mestizos only those individuals who had been born in Mexico for three generations, including their own. A Mexican Mestizo is defined as someone born in Mexico, who is a descendant of the original autochthonous inhabitants of the region and of individuals, mainly Spaniards, of Caucasian and/or African origin, who came to America during the sixteenth century. The study complies with the Declaration of Helsinki. The Institutional Bioethics and Research Committee approved the present study and all study subjects signed an informed consent letter.</p>
</sec>
<sec id="section4-1470320311419175">
<title>DNA extraction</title>
<p>Genomic DNA from whole blood containing EDTA was isolated by standard techniques.<sup><xref ref-type="bibr" rid="bibr14-1470320311419175">14</xref></sup></p>
</sec>
<sec id="section5-1470320311419175">
<title>Determination of the AGTR1 genotypes</title>
<p>The <italic>AGTR1</italic>-777 <italic>A&gt;T</italic> (rs275651), <italic>AGTR1</italic>-680 <italic>G&gt;T</italic> (rs275652), <italic>AGTR1</italic>-119 <italic>A&gt;G</italic> (rs275653) <italic>AGTR1</italic>+49227 <italic>C&gt;G</italic> (rs5183), and <italic>AGTR1</italic>+573T <italic>C&gt;T</italic> (rs5182) single nucleotide polymorphisms were genotyped using 5’ exonuclease TaqMan genotyping assays on an ABI Prism 7900HT Fast Real-Time PCR system, according to manufacturer’s instructions (Applied Biosystems, Foster City, USA) (<xref ref-type="table" rid="table1-1470320311419175">Table 1</xref>).</p>
<table-wrap id="table1-1470320311419175" position="float">
<label>Table 1.</label>
<caption><p>Studied polymorphisms</p></caption>
<graphic alternate-form-of="table1-1470320311419175" xlink:href="10.1177_1470320311419175-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">No.</th>
<th align="left">SNP name</th>
<th align="left">Ch position (pb)</th>
<th align="left">Gene region</th>
<th align="left">Alleles</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>rs275651</td>
<td>149897577</td>
<td>5′near region</td>
<td>T/A</td>
</tr>
<tr>
<td>2</td>
<td>rs275652</td>
<td>149897674</td>
<td>5′near region</td>
<td>T/G</td>
</tr>
<tr>
<td>3</td>
<td>rs275653</td>
<td>149898235</td>
<td>5′near region</td>
<td>A/G</td>
</tr>
<tr>
<td>4</td>
<td>rs5182</td>
<td>149942085</td>
<td>Exon 4</td>
<td>T/C</td>
</tr>
<tr>
<td>5</td>
<td>rs5183</td>
<td>149942574</td>
<td>3′near region</td>
<td>A/G</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320311419175">
<p>SNP: single nucleotide polymorphism.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-1470320311419175">
<title>Statistical analysis</title>
<p>Allele and genotype frequencies of the studied polymorphisms were obtained by direct counting. Hardy–Weinberg equilibrium (HWE) was calculated using the Chi-squared test. The significance of the difference between groups was determined using Mantel–Haenzel chi-square analysis. Fisher’s exact test was used when needed. Demographic and clinical variables between hypertensive and non-hypertensive groups were analyzed with Stata 8.0 for Windows software. In the exploratory analysis, numerical data had a different distribution from normal standard <italic>(Gaussian distribution) (Test of normality</italic> Shapiro Wilk’s <italic>p</italic> &gt; 0.05). Comparison of numerical variables between hypertensive and non-hypertensive individuals was done with Mann Whitney U-test and data are presented as median and percentiles 25 and 75. Categorical variables were analyzed with Chi-squared or Fisher tests as required and presented as absolute frequencies and proportions. Statistical significance was set at <italic>p</italic> ≤ 0.05. Inheritance hypothesis was tested according to four models: co-dominant, dominant, recessive, and heterozygous advantage. Logistic regression analysis was used in a bivariate way to estimate the risk of having hypertension between hypertensive and non-hypertensive individuals against the rs5182 polymorphism. Multiple logistic models were constructed in order to identify the variables that explain better the risk of developing hypertension between the studied groups. Models were constructed including one variable at a time, and final models included variables with biological relevance or with statistical significance, or both. Confounding bias was accepted when changes in estimated odds ratios (ORs) were equal <italic>or</italic> larger than 10%. When a principal effect model was reached, effect modification was also tested and interaction terms were constructed between the polymorphism and age, body mass index, triglycerides, alcohol consumption, and smoking habit; the terms were included in the model when the significance of the <italic>p</italic>-value was larger or equal to 0.20. Hosmer–Lemeshow Goodness of Fit test was performed for each multiple logistic model. Pairwise linkage disequilibrium (LD, D′) estimations between polymorphisms and haplotype reconstruction were performed with Haploview version 4:1 (Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA).</p>
</sec>
</sec>
<sec id="section7-1470320311419175" sec-type="results">
<title>Results</title>
<sec id="section8-1470320311419175">
<title>Characteristics of the study sample</title>
<p>The demographic and clinical characteristics are shown in <xref ref-type="table" rid="table2-1470320311419175">Table 2</xref>. Similar age and gender distribution was observed between hypertensive and non-hypertensive individuals. However, body mass index, triglyceride, glucose, alcohol consumption, and type 2 diabetes mellitus were higher in hypertensive than in non- hypertensive individuals. There were no significant differences between the hypertensive and non-hypertensive individuals for smoking status and cholesterol levels.</p>
<table-wrap id="table2-1470320311419175" position="float">
<label>Table 2.</label>
<caption><p>Cardiovascular risk factors distribution between normal and high blood pressure subjects<sup><xref ref-type="table-fn" rid="table-fn1-1470320311419175">a</xref></sup></p></caption>
<graphic alternate-form-of="table2-1470320311419175" xlink:href="10.1177_1470320311419175-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="left" colspan="6">Blood Pressure</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
<tr>
<th/>
<th align="left" colspan="3">Normal (&lt; 140/90 mmHg) (<italic>n</italic> = 371)</th>
<th align="left" colspan="3">High (≥ 140/90 mmHg) (<italic>n</italic> = 239)</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol consumption</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Never</td>
<td>177 (48)</td>
<td/>
<td/>
<td>94 (39)</td>
<td/>
<td/>
<td>0.025</td>
</tr>
<tr>
<td> &gt;= 6 g/day</td>
<td>194 (52)</td>
<td/>
<td/>
<td>145 (61)</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Type 2 diabetes mellitus</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Yes</td>
<td>71 (19)</td>
<td/>
<td/>
<td>33 (14)</td>
<td/>
<td/>
<td>0.054</td>
</tr>
<tr>
<td> No</td>
<td>300 (81)</td>
<td/>
<td/>
<td>206 (86)</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<th/>
<th align="left">P25</th>
<th align="left">median</th>
<th align="left">P75</th>
<th align="left">P25</th>
<th align="left">median</th>
<th align="left">P75</th>
<th/>
</tr>
<tr>
<td>Age (years)</td>
<td>52</td>
<td>56</td>
<td>62</td>
<td>51</td>
<td>58</td>
<td>63</td>
<td>0.0451</td>
</tr>
<tr>
<td>Body mass index (kg/m<sup>2</sup>)</td>
<td>24.5</td>
<td>27.1</td>
<td>29.8</td>
<td>26.8</td>
<td>29.3</td>
<td>32.1</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>105</td>
<td>142</td>
<td>191</td>
<td>117</td>
<td>160</td>
<td>215</td>
<td>0.0029</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>83</td>
<td>90</td>
<td>115</td>
<td>88</td>
<td>95</td>
<td>108</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1470320311419175">
<label>a</label>
<p>Only the variables with a significant <italic>p</italic>-value are shown; gender distribution, values of total cholesterol, LDL, and HDL were similar in hypertensive and non-hypertensive individuals.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-1470320311419175">
<title>Allele and genotype frequencies</title>
<p>Allele and genotype frequencies of gene polymorphisms in hypertensive and non-hypertensive individuals are shown in <xref ref-type="table" rid="table3-1470320311419175">Table 3</xref>. Observed and expected frequencies in all polymorphic sites were in Hardy–Weinberg equilibrium. Similar distribution of the rs275651, rs275652, rs275653, and rs5183 polymorphisms was observed in hypertensive and non-hypertensive individuals. However, different distribution of rs5182 genotypes was observed in hypertensive and non-hypertensive individuals (<italic>p</italic> = 0.016). The inheritance hypothesis for this polymorphism was tested according to four models: co-dominant, dominant, recessive, and heterozygous advantage (<xref ref-type="table" rid="table4-1470320311419175">Table 4</xref>). According to the co-dominant model, individuals with <italic>CC</italic> genotype had a 1.83-fold increased risk of developing hypertension (<italic>p</italic> = 0.009). The co-dominant model in this study was selected on the basis of Akaike Information Criteria; this model allows every genotype to give a different and non-additive risk. With respect to the analysis of the interactions between co-dominant model and covariates, after adjusting for known risk factors, we found that there was a significant contribution of age, BMI, triglycerides, alcohol consumption to the inheritance model. We identified the smoking habit as a significant protective factor in this model, perhaps because patients stopped smoking or reduced the number of cigarettes that they usually smoke (<xref ref-type="table" rid="table5-1470320311419175">Table 5</xref>). The analysis of linkage disequilibrium of the <italic>AGTR1</italic> polymorphisms (rs275651, rs275652, rs275653, rs5183, and rs5182) is shown in <xref ref-type="table" rid="table6-1470320311419175">Table 6</xref>. The polymorphisms were distributed in two blocks; block 1 included the rs275651, rs275652, and rs275653 polymorphisms, whereas block 2 included the rs5183 and rs5182 polymorphisms (<xref ref-type="fig" rid="fig1-1470320311419175">Figure 1</xref>). Distribution of block 1 was similar in hypertensive and non-hypertensive individuals. However, distribution of block 2 was different, with increased frequency of the <italic>CA</italic> haplotype and decreased frequency of the <italic>TA</italic> haplotype in the hypertensive individuals when compared to non-hypertensive individuals (<italic>p</italic> = 0.015, OR = 1.33, 95% confidence interval [CI] = 1.06–1.68 and <italic>p</italic> = 0.019, OR = 0.75, 95% CI = 0.59–0.94, respectively) (<xref ref-type="table" rid="table6-1470320311419175">Table 6</xref>).</p>
<table-wrap id="table3-1470320311419175" position="float">
<label>Table 3.</label>
<caption><p>Allele and genotype distribution of AGTR1 polymorphisms in non-hypertensive and hypertensive individuals</p></caption>
<graphic alternate-form-of="table3-1470320311419175" xlink:href="10.1177_1470320311419175-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">SNP</th>
<th align="left" colspan="3">Non hypertensive (<italic>n</italic> = 371) Hypertensive (<italic>n</italic> = 239) (<italic>n</italic>%) (<italic>n</italic>%)</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs275651 (–777 A/T)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Alleles</td>
<td>A</td>
<td>79 (10.6)</td>
<td>49 (10.3)</td>
<td/>
</tr>
<tr>
<td/>
<td>T</td>
<td>663 (89.4)</td>
<td>429 (89.7)</td>
<td/>
</tr>
<tr>
<td> Genotypes</td>
<td>AA</td>
<td>8 (2.2)</td>
<td>5 (2.1)</td>
<td>NS</td>
</tr>
<tr>
<td/>
<td>AT</td>
<td>63 (16.9)</td>
<td>39 (16.3)</td>
<td/>
</tr>
<tr>
<td/>
<td>TT</td>
<td>300 (80.9)</td>
<td>195 (81.6)</td>
<td/>
</tr>
<tr>
<td>rs275652 (–680 G/T)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Alleles</td>
<td>G</td>
<td>80 (10.7)</td>
<td>51 (10.7)</td>
<td/>
</tr>
<tr>
<td/>
<td>T</td>
<td>662 (89.3)</td>
<td>427 (89.3)</td>
<td/>
</tr>
<tr>
<td> Genotypes</td>
<td>GG</td>
<td>3 (0.9)</td>
<td>5 (2.1)</td>
<td>NS</td>
</tr>
<tr>
<td/>
<td>GT</td>
<td>74 (19.9)</td>
<td>41 (17.2)</td>
<td/>
</tr>
<tr>
<td/>
<td>TT</td>
<td>294 (79.2)</td>
<td>193 (80.7)</td>
<td/>
</tr>
<tr>
<td>rs275653 (–119 A/G)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Alleles</td>
<td>A</td>
<td>664 (89.5)</td>
<td>433 (90.6)</td>
<td/>
</tr>
<tr>
<td/>
<td>G</td>
<td>78 (10.5)</td>
<td>45 (9.4)</td>
<td>NS</td>
</tr>
<tr>
<td> Genotypes</td>
<td>AA</td>
<td>296 (79.8)</td>
<td>198 (82.8)</td>
<td/>
</tr>
<tr>
<td/>
<td>AG</td>
<td>72 (19.4)</td>
<td>37 (15.5)</td>
<td/>
</tr>
<tr>
<td/>
<td>GG</td>
<td>3 (0.8)</td>
<td>4 (1.7)</td>
<td/>
</tr>
<tr>
<td>rs5183 (49227 A/G)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Alleles</td>
<td>A</td>
<td>708 (95.4)</td>
<td>457 (95.6)</td>
<td/>
</tr>
<tr>
<td/>
<td>G</td>
<td>34 (4.6)</td>
<td>21 (4.4)</td>
<td/>
</tr>
<tr>
<td> Genotypes</td>
<td>AA</td>
<td>339 (91.4)</td>
<td>219 (91.6)</td>
<td>NS</td>
</tr>
<tr>
<td/>
<td>AG</td>
<td>30 (8.1)</td>
<td>19 (8)</td>
<td/>
</tr>
<tr>
<td/>
<td>GG</td>
<td>2 (0.5)</td>
<td>1 (0.4)</td>
<td/>
</tr>
<tr>
<td>rs5182 (+573 C/T)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Alleles</td>
<td>C</td>
<td>325 (44)</td>
<td>245 (51)</td>
<td/>
</tr>
<tr>
<td/>
<td>T</td>
<td>417 (56)</td>
<td>233 (49)</td>
<td/>
</tr>
<tr>
<td> Genotypes</td>
<td><bold>CC</bold></td>
<td><bold>69 (18.6)</bold></td>
<td><bold>68 (28.5)</bold></td>
<td><bold>0.016</bold></td>
</tr>
<tr>
<td/>
<td>CT</td>
<td>187 (50.4)</td>
<td>109 (45.6)</td>
<td/>
</tr>
<tr>
<td/>
<td>TT</td>
<td>115 (31)</td>
<td>62 (25.9)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1470320311419175">
<p>NS: not significant; SNP: single nucleotide polymorphism.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-1470320311419175" position="float">
<label>Table 4.</label>
<caption><p>Risk analysis (rs5182 polymorphism) as function of the inheritance model in hypertensive and non-hypertensive individuals<sup><xref ref-type="table-fn" rid="table-fn4-1470320311419175">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table4-1470320311419175" xlink:href="10.1177_1470320311419175-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Inheritance model</th>
<th align="left">Genotype</th>
<th align="left">OR</th>
<th align="left">95% CI</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td/>
<td>TT</td>
<td>1.0</td>
<td/>
<td/>
</tr>
<tr>
<td>Co-dominant</td>
<td>CT</td>
<td>1.08</td>
<td>0.733–1.595</td>
<td>NS</td>
</tr>
<tr>
<td/>
<td><bold>CC</bold></td>
<td><bold>1.83</bold></td>
<td><bold>1.159–2.883</bold></td>
<td><bold>0.009</bold></td>
</tr>
<tr>
<td>Recessive</td>
<td>CC vs.</td>
<td>1.0</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td>CT+TT</td>
<td>1.282</td>
<td>0.892–1.844</td>
<td>NS</td>
</tr>
<tr>
<td>Dominant</td>
<td>TT vs.</td>
<td>1.0</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td>CT+CC</td>
<td>0.780</td>
<td>0.542–1.121</td>
<td>NS</td>
</tr>
<tr>
<td>Heterozygous advantage</td>
<td>CT vs.</td>
<td>1.0</td>
<td/>
<td/>
</tr>
<tr>
<td/>
<td>CC+TT</td>
<td>1.212</td>
<td>0.875–1.680</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1470320311419175">
<p>OR, odds ratio; CI, confidence interval. <sup>a</sup>Sample output of association models for binary response. Four inheritance models are fitted, which correspond to different parameterizations or groupings of the genotypes. Akaike’s Information Criterion (AIC) was used to select the best model for a specific polymorphism. The inheritance model with less AICs is the co-dominant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-1470320311419175" position="float">
<label>Table 5.</label>
<caption><p>Risk assessment in the rs5183 polymorphism using the co-dominant inheritance model between hypertensive and non-hypertensive individuals<sup><xref ref-type="table-fn" rid="table-fn5-1470320311419175">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table5-1470320311419175" xlink:href="10.1177_1470320311419175-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="left">OR</th>
<th align="left">95% CI</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs5183 (co-dominant)</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Genotypes:</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> TT</td>
<td>1</td>
<td/>
<td/>
</tr>
<tr>
<td> CT</td>
<td>1.082</td>
<td>0.713–1.643</td>
<td>NS</td>
</tr>
<tr>
<td> <bold>CC</bold></td>
<td><bold>1.854</bold></td>
<td>1.139–3.016</td>
<td><bold>0.013</bold></td>
</tr>
<tr>
<td>Age (years)</td>
<td>1.025</td>
<td>1.260–2.600</td>
<td>0.020</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>1.136</td>
<td>1.088–1.186</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>1.003</td>
<td>1.001–1.005</td>
<td>0.003</td>
</tr>
<tr>
<td>Alcohol consumption (Yes/No)</td>
<td>1.807</td>
<td>1.260–2.600</td>
<td>0.001</td>
</tr>
<tr>
<td>Smoking (Yes/No)</td>
<td>0.463</td>
<td>0.321–0.668</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1470320311419175">
<p>OR, odds ratio; CI; confidence interval; NS, Not significant. <sup>a</sup>The data were adjusted for age, body mass index (BMI), triglycerides, alcohol consumption and smoking habit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-1470320311419175" position="float">
<label>Table 6.</label>
<caption><p>AGTR1 haplotype frequencies in hypertensive and non-hypertensive individuals<sup><xref ref-type="table-fn" rid="table-fn6-1470320311419175">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table6-1470320311419175" xlink:href="10.1177_1470320311419175-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Haplotypes</th>
<th align="left" colspan="2">Frequencies</th>
<th align="left">OR (95% CI)</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
<tr>
<th/>
<th align="left">HT</th>
<th align="left">NH</th>
<th/>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>Block 1 (rs275651, rs275652, rs275653)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> T-T-A</td>
<td>0.869</td>
<td>0.875</td>
<td/>
<td/>
</tr>
<tr>
<td> A-G-G</td>
<td>0.076</td>
<td>0.091</td>
<td/>
<td/>
</tr>
<tr>
<td>Block 2 (rs5182, rs5183)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> <bold>T-A</bold></td>
<td><bold>0.483</bold></td>
<td><bold>0.554</bold></td>
<td><bold>0.75 (0.59–0.94)</bold></td>
<td><bold>0.019</bold></td>
</tr>
<tr>
<td> <bold>C-A</bold></td>
<td><bold>0.472</bold></td>
<td><bold>0.401</bold></td>
<td><bold>1.33 (1.06–1.68)</bold></td>
<td><bold>0.015</bold></td>
</tr>
<tr>
<td> C-G</td>
<td>0.038</td>
<td>0.039</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1470320311419175">
<p>HT, hypertensive; NH, non-hypertensive; OR, odds ratio; CI, confidence interval; <italic>p</italic>-value &lt; 0.005. <sup>a</sup>The order of the polymorphisms in the haplotypes is according to the positions in the chromosome.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1470320311419175" position="float">
<label>Figure 1.</label>
<caption><p>Haploview linkage disequilibrium graph of AGTR1 gene. Pairwise linkage disequilibrium coefficients D′ × 100 are shown in each cell (D′ values of 1.0 are not shown). Standard color scheme of Haploview was applied for linkage disequilibrium color display (logarithm of odds [LOD] score ≥ 2 and D′ = 1, shown in bright red; LOD score ≥2 and D′&lt; 1 shown in shades of pink/red; LOD score &lt;2 and D′&lt; 1 shown in white).</p></caption>
<graphic xlink:href="10.1177_1470320311419175-fig1.tif"/>
</fig>
</sec>
</sec>
<sec id="section10-1470320311419175" sec-type="discussion">
<title>Discussion</title>
<p>Hypertension involves interactions among genetic, environmental, demographic, vascular, and neuroendocrine factors. Essential hypertension is the most frequent diagnosis in this syndrome; the etiology has not been identified. However, a number of risk factors underlying essential hypertension have been identified, including age, gender, and genetics. In some cases, the control of environmental risk factors associated with an appropriate drug/dose can normalize the blood pressure. From the genetic point of view, special attention has been given to the study of genes implicated in the renin–angiotensin system. Several clinical studies have reported an association between <italic>AGTR1</italic> genotype and pathological phenotypes, including essential hypertension, cardiovascular disease, and diabetic nephropathy. In the present study, we determined five polymorphisms of the <italic>AGTR1</italic> gene in a group of Mexican individuals with and without hypertension. Three polymorphisms are located in the 5′ region (rs275651, rs275652, and rs275653) and the other two in the 3′ region (rs5182 and rs5183). An increased frequency of the rs5182 <italic>C</italic> allele and <italic>CC</italic> genotype was observed in hypertensive individuals, suggesting a role of this polymorphism in the genetic susceptibility of such individuals to hypertension. This polymorphism has been studied in several diseases with contradictory results. Bonnardeaux et al.<sup><xref ref-type="bibr" rid="bibr15-1470320311419175">15</xref></sup> screened the exon 5 and the 3′-untranslated region, and identified five frequent polymorphisms: <italic>+573</italic> (rs5182), <italic>+1062, +1166, +1517</italic>, and <italic>+1878</italic>; in this study, the authors used case–control and linkage studies to examine the association between <italic>AGTR1</italic> gene polymorphisms and essential hypertension.<sup><xref ref-type="bibr" rid="bibr15-1470320311419175">15</xref></sup> Of the five polymorphisms that they described, only the <italic>+1166</italic> in the 3′-untranslated region was significantly associated with hypertension. This association was most pronounced in those with an earlier onset of hypertension or more severe hypertension. On the other hand, Chaves et al.<sup><xref ref-type="bibr" rid="bibr16-1470320311419175">16</xref></sup> found that the rs5182 <italic>TT</italic> genotype might be a genetic protective factor for urinary albumin excretion in patients with essential hypertension. Zhu et al.<sup><xref ref-type="bibr" rid="bibr17-1470320311419175">17</xref></sup> reported a haplotype containing the rs5182 <italic>C</italic> and rs5183 <italic>G</italic> alleles, possibly associated with hypertension in African-Americans (<italic>p</italic> &lt; 0.05). In a haplotype transmission disequilibrium test, this ‘<italic>CG’</italic> haplotype was transmitted over to hypertensive offspring (<italic>p</italic> = 0.0002). No association was found in Caucasian Americans in this study.<sup><xref ref-type="bibr" rid="bibr17-1470320311419175">17</xref></sup> In our study, the haplotype analysis showed that the <italic>AGTR1</italic> polymorphisms were distributed in two blocks; one of them included the rs5182 and rs5183 polymorphisms (block 2). In this block, the haplotype associated with hypertension was ‘<italic>CA</italic>’; this haplotype includes the same rs5182 allele as the haplotype reported by Zhu; however, it includes a different allele in the rs5183 polymorphism. This suggests an important participation of the rs5182 polymorphism in the genetic susceptibility to hypertension. Contrary to the participation of the rs5182 polymorphism in hypertension, in which the <italic>C</italic> allele has been associated with susceptibility, Israni et al.<sup><xref ref-type="bibr" rid="bibr18-1470320311419175">18</xref></sup> reported that the rs5182 <italic>T</italic> allele was associated with a 50% decline in the estimated glomerular filtration rate after kidney transplant. The authors suggest that this polymorphism may impact renal allograft function through several potential mechanisms. In spite that the rs5182 polymorphism is not in the coding region of the gene, this polymorphism could be in linkage disequilibrium with a nearby functional polymorphism or may result in a splice site variation that alters the function of this AGT receptor. The different participation of the rs5182 polymorphism in hypertension and in the renal function decline supports the complexity of interactions and mechanisms through which the <italic>AGTR1</italic> gene could participate in renal and vascular function.</p>
<p>In addition, intervention studies have suggested that <italic>AGTR1</italic> gene polymorphisms may predict the physiological response to pharmacological maneuvers. Brugts et al.<sup><xref ref-type="bibr" rid="bibr19-1470320311419175">19</xref></sup> developed a genetic profile to predict the treatment benefit of angiotensin converting enzyme (ACE) inhibitors in patients with coronary artery disease. This study included the analysis of 52 polymorphisms located in the renin–angiotensin aldosterone system (RAAS) and the kallikrein–bradykinin pathway. Two polymorphisms located in the <italic>AGTR1</italic> gene were significantly associated with the treatment benefit. One of these polymorphism was the rs5182, associated with hypertension in our study. Similar studies reported association of RAAS polymorphisms with response to ACE-inhibitor therapy.<sup><xref ref-type="bibr" rid="bibr20-1470320311419175">20</xref>,<xref ref-type="bibr" rid="bibr21-1470320311419175">21</xref></sup></p>
<p>To our knowledge this is the first paper that describes the association between AGTR1 gene polymorphisms and hypertension in the Mexican population. The AGTR1 +573 C/T (rs5182) polymorphism was associated with the risk of developing hypertension in this population. However, our study had some limitations. First, we only studied five AGTR1 gene polymorphisms that have been associated with hypertension in previous studies. We did not examine other polymorphisms that might be associated with this disease. Second, the findings of the study need to be validated in an independent cohort of patients. Efforts are underway to test these AGTR1 polymorphisms in another cohort of Mexican individuals with and without hypertension.</p>
<p>In summary, our results suggest that the <italic>AGTR1 +573 C/T</italic> (rs5182) gene polymorphism could be involved in the risk of developing hypertension in Mexican individuals. In our study, it was possible to identify one risk haplotype for developing hypertension. Additional studies in other populations and in other genes of the renin–angiotensin system could help to define the susceptibility markers for hypertension.</p>
</sec>
</body>
<back>
<ack>
<p>This work was submitted in partial fulfillment of the requirements for the PhD degree by Nancy L Martínez-Rodríguez at the Graduate Studies in Biomedical Sciences of the Universidad Nacional Autónoma de México. Nancy L Martínez-Rodríguez was supported by a fellowship from the Consejo Nacional de Ciencia y Tecnología (CONACyT).</p>
<p>The authors are grateful to the study participants. Institutional Review Board approval was obtained for all sample collections.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This work was supported in part by grants from the Consejo Nacional de Ciencia y Tecnología (Project number 87356).</p>
</fn>
<fn fn-type="conflict">
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320311419175">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Collins</surname><given-names>R</given-names></name>
<name><surname>Peto</surname><given-names>R</given-names></name>
<name><surname>MacMahon</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context</article-title>. <source>Lancet</source> <year>1990</year>; <volume>335</volume>: <fpage>827</fpage>–<lpage>838</lpage>.</citation>
</ref>
<ref id="bibr2-1470320311419175">
<label>2.</label>
<citation citation-type="journal">
<article-title>World Health Organization/International Society of Hypertension Guidelines for the management of hypertension</article-title>. <source>J Hypertension</source> <year>2003</year>; <volume>17</volume>: <fpage>151</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr3-1470320311419175">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schork</surname><given-names>NJ</given-names></name>
</person-group>. <article-title>Genetically complex cardiovascular traits. Origins, problems, and potential solutions</article-title>. <source>Hypertension</source> <year>1997</year>; <volume>29</volume>: <fpage>145</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr4-1470320311419175">
<label>4.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Ward</surname><given-names>R</given-names></name>
</person-group>. <article-title>Familial aggregation and genetic epidemiology of blood pressure</article-title>. In: <person-group person-group-type="editor">
<name><surname>Laragh</surname><given-names>JH</given-names></name>
<name><surname>Brenner</surname><given-names>BM</given-names></name>
</person-group> (eds). <source>Hypertension: pathophysiology, dDiagnosis and management</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Raven Press</publisher-name>; <year>1995</year>, pp. <fpage>67</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr5-1470320311419175">
<label>5.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Sealy</surname><given-names>JE</given-names></name>
<name><surname>Laragh</surname><given-names>JH</given-names></name>
</person-group>. <article-title>The rennin–angiotensin–aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis</article-title>. In: <person-group person-group-type="editor">
<name><surname>Laragh</surname><given-names>JH</given-names></name>
<name><surname>Brenner</surname><given-names>BM</given-names></name>
</person-group> (eds). <source>Hypertension: pathophysiology, dDiagnosis, and management</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Raven Press</publisher-name>; <year>1995</year>, pp. <fpage>1763</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr6-1470320311419175">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S</given-names></name>
<name><surname>Iwao</surname><given-names>H</given-names></name>
</person-group>. <article-title>Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases</article-title>. <source>Pharmacol Rev</source> <year>2000</year>; <volume>52</volume>: <fpage>11</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr7-1470320311419175">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chiu</surname><given-names>AT</given-names></name>
<name><surname>Herblin</surname><given-names>WF</given-names></name>
<name><surname>McCall</surname><given-names>DE</given-names></name>
<etal/>
</person-group>. <article-title>Identification of angioensin II receptor subtypes</article-title>. <source>Biochem Biophys Res Commun</source> <year>1989</year>; <volume>165</volume>: <fpage>196</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr8-1470320311419175">
<label>8.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Gasparo</surname><given-names>M</given-names></name>
<name><surname>Bullock</surname><given-names>G</given-names></name>
</person-group>. <article-title>The AT1 and AT2 angiotensin receptors</article-title>. In: <person-group person-group-type="editor">
<name><surname>Oparil</surname><given-names>S</given-names></name>
<name><surname>Webber</surname><given-names>M</given-names></name>
</person-group> (eds). <source>Hypertension: a companion to Brenner &amp; Rector′s The Kidney</source>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>WB Saunders Company</publisher-name>, <year>2000</year>, pp. <fpage>101</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr9-1470320311419175">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guo</surname><given-names>D</given-names></name>
<name><surname>Furuta</surname><given-names>H</given-names></name>
<name><surname>Mizukoshi</surname><given-names>M</given-names></name>
<name><surname>Inagami</surname><given-names>T</given-names></name>
</person-group>. <article-title>The genomic organization of human angiotensin II type 1 receptor</article-title>. <source>Biochem Biophys Res Commun</source> <year>1994</year>; <volume>200</volume>: <fpage>313</fpage>–<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr10-1470320311419175">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Namazi</surname><given-names>S</given-names></name>
<name><surname>Monabati</surname><given-names>A</given-names></name>
<name><surname>Ardeshir-Rouhani-Fard</surname><given-names>S</given-names></name>
<name><surname>Azarpira</surname><given-names>N</given-names></name>
</person-group>. <article-title>Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in Iranian population</article-title>. <source>Mol Carcinog</source> <year>2010</year>: <volume>49</volume>: <fpage>1022</fpage>–<lpage>1030</lpage>.</citation>
</ref>
<ref id="bibr11-1470320311419175">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anbazhagan</surname><given-names>K</given-names></name>
<name><surname>Sampathkumar</surname><given-names>K</given-names></name>
<name><surname>Ramakrishnan</surname><given-names>M</given-names></name>
<name><surname>Gomathi</surname><given-names>P</given-names></name>
<name><surname>Gomathi</surname><given-names>S</given-names></name>
<name><surname>Selvam</surname><given-names>GS</given-names></name>
</person-group>. <article-title>Analysis of polymorphism in renin angiotensin system and other related genes in South Indian chronic kidney disease patients</article-title>. <source>Clin Chim Acta</source> <year>2009</year>; <volume>406</volume>: <fpage>108</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr12-1470320311419175">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>S</given-names></name>
<name><surname>Schaa</surname><given-names>K</given-names></name>
<name><surname>Cooper</surname><given-names>ME</given-names></name>
<etal/>
</person-group>. <article-title>Genetic contributions to the development of retinopathy of prematurity</article-title>. <source>Pediatr Res</source> <year>2009</year>; <volume>65</volume>: <fpage>193</fpage>–<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr13-1470320311419175">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pop</surname><given-names>D</given-names></name>
<name><surname>Zdrenghea</surname><given-names>D</given-names></name>
<name><surname>Procociuc</surname><given-names>LM</given-names></name>
<name><surname>Popal</surname><given-names>A</given-names></name>
</person-group>. <article-title>Gene polymorphism of angiotensin-converting enzyme and angiotensin II type 1 receptor in patients with congestive heart failure</article-title>. <source>Rom J Intern Med</source> <year>2007</year>; <volume>45</volume>: <fpage>349</fpage>–<lpage>354</lpage>.</citation>
</ref>
<ref id="bibr14-1470320311419175">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>SA</given-names></name>
<name><surname>Dykes</surname><given-names>DD</given-names></name>
<name><surname>Polesky</surname><given-names>HF</given-names></name>
</person-group>. <article-title>A simple salting out procedure for extracting DNA from human nucleated cells</article-title>. <source>Nucleic Acids Res</source> <year>1988</year>; <volume>16</volume>: <year>1215</year>.</citation>
</ref>
<ref id="bibr15-1470320311419175">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonnardeaux</surname><given-names>A</given-names></name>
<name><surname>Davies</surname><given-names>E</given-names></name>
<name><surname>Jeunemaitre</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension</article-title>. <source>Hypertension</source> <year>1994</year>; <volume>24</volume>: <fpage>63</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr16-1470320311419175">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaves</surname><given-names>FJ</given-names></name>
<name><surname>Pascual</surname><given-names>JM</given-names></name>
<name><surname>Rovira</surname><given-names>E</given-names></name>
<name><surname>Argmengod</surname><given-names>ME</given-names></name>
<name><surname>Redon</surname><given-names>J</given-names></name>
</person-group>. <article-title>Angiotensin II AT1 receptor gene polymorphism and microalbuminuria in essential hypertension</article-title>. <source>Am J Hypertens</source> <year>2001</year>; <volume>14</volume>: <fpage>364</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr17-1470320311419175">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>X</given-names></name>
<name><surname>Chang</surname><given-names>YPC</given-names></name>
<name><surname>Yan</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Associations between hypertension and genes in the renin-angiotensin system</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>41</volume>: <fpage>1027</fpage>–<lpage>1034</lpage>.</citation>
</ref>
<ref id="bibr18-1470320311419175">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Israni</surname><given-names>AK</given-names></name>
<name><surname>Li</surname><given-names>N</given-names></name>
<name><surname>Sidhwani</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Association of hypertension genotypes and decline in renal function after kidney transplantation</article-title>. <source>Transplantation</source> <year>2007</year>; <volume>84</volume>: <fpage>1240</fpage>–<lpage>1247</lpage>.</citation>
</ref>
<ref id="bibr19-1470320311419175">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brugts</surname><given-names>JJ</given-names></name>
<name><surname>Isaacs</surname><given-names>A</given-names></name>
<name><surname>Boersma</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>: <fpage>1854</fpage>–<lpage>1864</lpage>.</citation>
</ref>
<ref id="bibr20-1470320311419175">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brugts</surname><given-names>JJ</given-names></name>
<name><surname>de Maat</surname><given-names>MP</given-names></name>
<name><surname>Boersma</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease</article-title>. <source>Cardiovasc Drugs Ther</source> <year>2009</year>; <volume>23</volume>: <fpage>171</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr21-1470320311419175">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brugts</surname><given-names>JJ</given-names></name>
<name><surname>Isaacs</surname><given-names>A</given-names></name>
<name><surname>de Maat</surname><given-names>MP</given-names></name>
<etal/>
</person-group>. <article-title>A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals</article-title>. <source>J Hypertens</source> <year>2011</year>; <volume>29</volume>: <fpage>509</fpage>–<lpage>519</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>